Social Media Ideas for The Psychedelic Practitioner

The Psychedelic Practitioner Issue 5: Groups in Practice

Where Psychedelic Treatments Fit in Modern Clinical Care

How psychedelic-assisted therapy may complement ongoing mental health care through collaborative treatment models, continuity, and patient-centered support.

When Psychedelics Work Therapeutically

May 25, 2026 | Source: Psychology Today | by Antonieta Contreras I have a habit of jumping toward the next promising thing the moment I hear about it. That is what happened when p...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

Managing Suggestibility in Psychedelic-Assisted Therapy

Suggestibility is a double-edged sword in psychedelic-assisted therapy: It often serves as a catalyst for healing but can also leaves clients vulnerable to bias and misconduct.

The Buddha Was a Revolutionary

Psychedelic Sangha founder Chris Kelley on approaching art as a mahasidda and the useful fictions of mind-altering substances The post The Buddha Was a Revolutionary appeared first...

Psychedelic medicine and insurance: Scientific and strategic allegiance for the insurance industry

'The era of psychedelic medicine has now arrived'

Clinical Rigor Meets Ancient Wisdom: Sayulita Wellness Retreat Pioneers Safe, Medically Supervised Psychedelic Therapy i...

Sayulita Wellness Retreat has introduced a pioneering hybrid model in Riviera Nayarit, Mexico, that pairs strict Western medical safety with traditional plant medicine ceremonies....

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

Miracle or Minefield? The Alzheimer’s Case Report A Case Report published in Frontiers in Neuroscience late last month (Lago et al., 2026) caused quite a stir, with various media o...

Where Psychedelics Meet Madness: Intersections, Lessons and a Call for Transformative Research Agendas

If I had been supported to integrate my altered-state experiences 36 years ago, how much suffering could have been alleviated? The post Where Psychedelics Meet Madness: Intersectio...

Psychedelic researchers confront the hard questions as medical research expedited

To understand psychedelics — those powerful and cryptic agents of the mind — scientists are exploring uncharted landscapes. “We don’t yet really know why psilocybin or other psyche...

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Last month, our Editor, Josh Hardman, attended the American Psychiatric Association’s (APA) five-day annual meeting in San Francisco. There, he took the temperature of a field that...

Addressing US Demand for Psychedelic Medicines in the Face of Scientific Uncertainty

Published online by Cambridge University Press:  15 October 2025 Holly Fernandez Lynch, Xinping Hu and Alison Bateman-House Abstract Psychedelic medicines hold the promise of thera...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

Today, we’re introducing Field Notes. Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that provide our Pα+ readers with a pulse on the recent...

7 Lessons From 7 Years With Psychedelics

Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.Continue reading on Medium »

Mushrooms got him off antidepressants, so he built TripSitter

Writer John Biggs wanted no part of psychedelics, he writes in his newsletter — he pictured being "trapped in a room with a bunch of weirdos while they sang songs and listened to t...

Tryp-Expo-Messe für Psychedelika: Die Dosis macht das Gift

Fliegenpilze, Froschgift und Breathwork: Auf Europas größter Messe für Psychedelika treffen alternative Therapieformen auf organisierten Rausch. mehr...

A psychedelics revival is overdue

R. Gordon Wasson was a Manhattan banker who fancied himself a mycologist. In 1955, after decades studying the mushrooms of ancient cultures, he traveled to the remote mountains of...

Psychedelics in psychiatry are not a neural reset

The history of psychiatry is often a story of our own impatience. When we look back at the era of the ice-pick lobotomy, we tend to view it as a distant, primitive horror. But if w...

'Third therapist in the room': Inside Israel's psychedelic trauma trial

Eight-hour sessions, two therapists, and MDMA as "a third therapist in the room." Inside Israel's race to reach the 60% of veterans standard therapy fails.

Natural Hallucinogens: Evolution’s Ecological Tools, Not Mere Chemical Byproducts

Natural hallucinogens—psychoactive compounds such as psilocybin, mescaline, and N,N-dimethyltryptamine (DMT)—have long captured human fascination due to their profound effects on p...

Is The UK’s Psychedelic Medicine Wave Getting Ahead Of NHS Reality?

For decades, psilocybin and MDMA were locked away in the same legal category as heroin: Schedule 1 drugs with no... The post Is The UK’s Psychedelic Medicine Wave Getting Ahead Of...

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalit...

Last summer, Germany’s medicines regulator quietly green-lit a psilocybin compassionate use program, the first such pathway in the European Union (see Germany Establishes EU’s Firs...

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens P...

It’s been an incredibly busy few weeks since our last Bulletin, with Psychedelic Alpha on the road in the U.S. (for APA’s annual meeting and a visit to Stanford and the valley), Th...